BIOGEN INC. Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31)
BIOGEN INC. (BIIB) had Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) of $0 as of 2013-03-31, per its 10-Q filed 2013-04-25.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLosses1 · last filed 2013-04-25
- 2013-03-31: Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) $0.00.
- 2012-12-31: Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) -$1.90M; Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) as first filed $1.90M.
- 2012-09-30: Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) $1.40M.
- 2012-06-30: Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) $1.80M.
| Period end | Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) | Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) as first filed |
|---|---|---|
| 2013-03-31 | $0.00 10-Q · filed 2013-04-25 | |
| 2012-12-31 | -$1.90M 10-Q · filed 2013-04-25 | $1.90M 10-K · filed 2013-02-05 |
| 2012-09-30 | $1.40M 10-Q · filed 2012-10-25 | |
| 2012-06-30 | $1.80M 10-Q · filed 2012-07-24 | |
| 2012-03-31 | $1.80M 10-Q · filed 2012-05-01 | |
| 2011-12-31 | $3.10M 10-K · filed 2013-02-05 | |
| 2011-09-30 | $2.60M 10-Q · filed 2011-10-28 | |
| 2011-06-30 | $900.00K 10-Q · filed 2011-07-26 | |
| 2010-12-31 | $1.30M 10-K · filed 2012-02-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |